Stay updated with breaking news from Mark Lanasa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancer Biomarker studies shed light on patient
Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancerBiomarker studies shed light on patient characteristics driving improved response to PD-(L)1 inhibitorsCAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland--(BUSINESS W...
Tislelizumab is now approved in seven indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative